Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators
Expert consensus identifies key mechanisms driving immunotherapy resistance in lung cancer and proposes trial designs to overcome them, guiding future research strategy.
This J Clin Oncol perspective from Lung-MAP investigators synthesizes current understanding of ICI resistance mechanisms in NSCLC and outlines recommendations for trial design to overcome resistance, drawing on multi-institution experience. This is an expert opinion piece without new primary data but from a high-impact, well-positioned investigator group.
What the study was
- Study design
- Expert perspective/commentary from Lung-MAP investigators
- Population
- NSCLC patients in clinical trials
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- J Clin Oncol
Why it surfaced
J Clin Oncol expert perspective from major NSCLC consortium; relevant background for ICI resistance pipeline context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.